Matrix Metallopeptidase 23A: A Potential Drug Target and Biomarker

Target Name: MMP23A

NCBI ID: G8511

MMP23A

Other Name(s): matrix metallopeptidase 23A (pseudogene) | MMP21 | MIFR-1 | Matrix metallopeptidase 23A (pseudogene) | MIFR

Matrix Metallopeptidase 23A: A Potential Drug Target and Biomarker

Matrix metallopeptidase 23A (MMP23A), also known as pseudogene, is a protein that is expressed in various tissues throughout the body, including skeletal muscles, heart, liver, and kidneys. It is a member of the matrix metallopeptidase (MMP) family, which includes a variety of enzymes that belong to the MMP1 to MMP13 subfamilies. MMP23A is one of the MMP enzymes that belong to the MMP2 subfamily.

The MMP2 subfamily is characterized by the presence of a unique catalytic domain that is composed of a series of zinc ions. This domain is responsible for the catalytic activity of the enzyme, as well as its ability to interact with other proteins. The MMP23A enzyme is characterized by the presence of a single zinc ion in its catalytic domain, which is located at the active site of the enzyme.

MMP23A is a critical enzyme for the regulation of matrix metallopeptidase activity, which is involved in the degradation of extracellular matrix (ECM) components such as collagen and casein. ECM components are removed from the body through the secretion of proteases, and the MMP enzymes play a critical role in this process. MMP23A is involved in the degradation of casein, which is a protein found in muscle tissue, heart muscle, and other tissues.

In addition to its role in ECM degradation, MMP23A is also involved in the regulation of cellular signaling processes. For example, it has been shown to be involved in the regulation of muscle cell growth and differentiation, as well as in the regulation of cell survival.

MMP23A is also a potential drug target in the treatment of various diseases. For example, it has been shown to be involved in the development of cancer, and may also be involved in the regulation of aging.

MMP23A is also a potential biomarker for certain diseases, such as cancer. The levels of MMP23A have been shown to be elevated in various types of cancer, and may be a useful indicator of the disease.

In conclusion, MMP23A is a matrix metallopeptidase enzyme that is expressed in various tissues throughout the body. It is involved in the regulation of ECM degradation and cellular signaling processes, and is a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of MMP23A in these processes and its potential as a drug.

Protein Name: Matrix Metallopeptidase 23A (pseudogene)

The "MMP23A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MMP23A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets